Zoetis reported business results on August 6, 2025, noting a 4% year-over-year revenue increase in the U.S. segment and FDA approval of a new indication for Simparica Trio.
1 report, 1 independent
Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Zoetis reported business results on August 6, 2025, noting a 4% year-over-year revenue increase in the U.S. segment and FDA approval of a new indication for Simparica Trio.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Zoetis
American animal health company
Nothing else this week.
- FDA
-
International
motor vehicle manufacturing company
Coverage
Newest first; wire copies grouped- ZacksZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised Zoetis, Inc. ZTS delivered second-quarter 2025 adjusted earnings (excluding one-time items) of $1.76 per share, which surpassed the Zacks